FHD-286

Near Add Your Location

Sorting 1 by

Accepting patients

FHD-286

A Phase 1, Multicenter, Open-Label, Dose Escalation Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Clinical Activity of Orally Administered FHD-286, as Monotherapy or Combination Therapy, in Subjects With Advanced Hematologic Malignancies
Learn more
  • BRG1 Inhibitor
  • BRM Inhibitor
  • Phase 1
  • Has results